Portal de Periódicos da CAPES

ESR1 Promoter Hypermethylation Does Not Predict Atypia in RPFNA nor Persistent Atypia after 12 Months Tamoxifen Chemoprevention

2008; American Association for Cancer Research; Volume: 17; Issue: 8 Linguagem: Inglês

10.1158/1055-9965.epi-07-2696

1538-7755

Joseph C. Baker, Julie H. Ostrander, Siya Lem, Gloria Broadwater, Gregory R. Bean, Nicholas C. D’Amato, Vanessa Goldenberg, Craig Rowell, Catherine Ibarra-Drendall, Tracey Grant, Patrick G. Pilié, Shauna N. Vasilatos, Michelle M. Troch, Victoria Scott, Lee G. Wilke, Carolyn Paisie, Sarah Rabiner, Alejandro Torres-Hernandez, Carola M. Zalles, Victoria L. Seewaldt,

Cancer and Skin Lesions

Abstract Purpose: Currently, we lack biomarkers to predict whether high-risk women with mammary atypia will respond to tamoxifen chemoprevention. Experimental Design: Thirty-four women with cytologic mammary atypia from the Duke University High-Risk clinic were offered tamoxifen chemoprevention. We tested whether ESR1 promoter hypermethylation and/or estrogen receptor (ER) protein expression by immunohistochemistry predicted persistent atypia in 18 women who were treated with tamoxifen for 12 months and in 16 untreated controls. Results: We observed a statistically significant decrease in the Masood score of women on tamoxifen chemoprevention for 12 months compared with control women. This was a significant interaction effect of time (0, 6, and 12 months) and treatment group (tamoxifen versus control) P = 0.0007. However, neither ESR1 promoter hypermethylation nor low ER expression predicted persistent atypia in Random Periareolar Fine Needle Aspiration after 12 months tamoxifen prevention. Conclusions: Results from this single institution pilot study provide evidence that, unlike for invasive breast cancer, ESR1 promoter hypermethylation and/or low ER expression is not a reliable marker of tamoxifen-resistant atypia. (Cancer Epidemiol Biomarkers Prev 2008;17(8):1884–90)